Radiotekhnika
Publishing house Radiotekhnika

"Publishing house Radiotekhnika":
scientific and technical literature.
Books and journals of publishing houses: IPRZHR, RS-PRESS, SCIENCE-PRESS


Тел.: +7 (495) 625-9241

 

Cytokines in blood serum in patients with bone tumors

Keywords:

I.V. Babkina, I.N. Kuznetsov, Russo E.Yu., L.T. Liyakina, V.G. Degtiyar


Bone tumors in total cancers are relatively rare, the etiology and pathogenesis of bone tumors has not yet been studied. Achieved over the last two decades in improving the diagnosis and treatment of certain types of bone sarcomas, particularly osteosarcoma, unfortunately, last observations does not show improve long-term outcomes, possibly because of the inconsistency of joint international efforts to identify new targets and introduction of new methods of treatment. This article presents a review of the literature and the results of their own research cytokines: granulocyte-macrophage colony - stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF), tumor necrosis factor (TNF-α), interferon-alpha (IFN-α) and – gamma (IFN-γ), interleukin -2 (IL-2), -6 (IL-6) and -16 (IL-16) in blood serum of patients with bone tumors prior specific treatment and healthy people. The role of cytokines in the pathogenesis of bone tumors are discussing.
References:
  1. Berezhnaja N.M., Goreckijj B.A. Biologicheskie ehffekty interlejjkina-2 i perspektivy ego ispolzovanija v immunoterapii zlokachestvennykh novoobrazovanijj // EHksperimentalnaja onkologija. 1989. T. 11. № 6. C. 38 – 44.
  2. Lebedev K.A., Ponjakina I.D. Immunnaja nedostatochnost (vyjavlenie i lechenie) // M.: Medicinskaja kniga. Nizhnijj Novgorod: Izd-vo NGMA. 2003. 443 s.
  3. Nasonov E.L. Faktor nekroza opukholi alfa – novaja mishen dlja protivovospalitelnojj terapii revmatoidnogo artrita // Russkijj medicinskijj zhurnal. 2000. T. 8. № 17. S. 718 – 722.
  4. Nedospasov S.A.Faktor nekroza opukholejj i limfotoksin: molekuljarnaja genetika, reguljacija i fiziologicheskaja rol // Genetika. 2003. T. 39. № 2. S. 207 – 214 .
  5. Suslova T.E. Provospalitelnye citokiny i ehndotelialnaja disfunkcija u bolnykh s koro­narnym aterosklerozom i u lic s otjagoshhennojj po aterosklerozu nasledstvennostju // Allergologija i immunologija. 2000. T. 1. № 2. S. 159.
  6. Akiyama T., Dass C.R., Shinoda Y., Kawano H., Tanaka S., Choong P.F. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts //J. Pharm. Pharmacol. 2010. V. 62. № 4. P. 470 – 476.
  7. Anderson P. Non-surgical treatment of pulmonary and extra-pulmonary metastases // Cancer Treat. Res. 2009. V. 152. P. 203 – 215.
  8. Arndt C.A.S., Koshkina N.V., Inwards C.Y., Hawkins D.S., Krailo M.D., Villaluna D., Anderson P.M., Goorin A.M., Blakely M.L., Bernstein M., Bell S.A., Ray K., Grendahl D.C., Marina N., Kleinerman E.S. Inhaled GM-CSF for first pulmonary reccurence of osteosarcoma; effects on disease free survival and immunomodulation: a report from the children’s oncology group // Clin. Cancer Res. 2010. V. 16. № 15. P. 4024 – 4030.
  9. Atanackovic D., Hildebrandt Y., Templin J., Cao Y., Keller C., Panse J., Meyer S., Reinhard H., Bartels K., Lajmi N., Sezer O., Zander A.R., Marx A.H., Uhlig R., Zustin J., Bokemeyer C., Kröger N.Role of interleukin 16 in multiple myeloma // J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 1005 – 1020.
  10. Avnet S., Longhi A., Salerno M., Halleen J.M., Perut F., Granchi D., Ferrari S., Bertoni F., Giunti A., Baldini N.Increased osteoclast activity is associated with aggressiveness of osteosarcoma //Int. J. Oncol.2008. V. 33. № 6. P. 1231 – 1238.
  11. Baron S., Hernandez J., Bekisz J., Poast J., Goldman N., Clouse K., Fields K., Bacot S., Wang J., Zoon K. Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro // J. Interferon Cytokine Res. 2007. V. 27. № 2. P. 157 – 163.
  12. Boye K., Andersen K., Tveito S. Øyjord T., Maelandsmo G.M.Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator // Tumour Biol. 2007. V. 28. № 1. P. 27 – 35.
  13. Cao Y., Luetkens T., Kobold S., Hildebrandt Y., Gordic M., Lajmi N., Meyer S., Bartels K., Zander A.R., Bokemeyer C., Kröger N., Atanackovic D.The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients//Exp. Hematol. 2010. V. 38. № 10. P. 860 – 867.
  14. Cates J.M., Friedman D.B., Seeley E.H., Dupont W.D., Schwartz H.S., Holt G.E., Caprioli R.M., Young P.P.Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis //Int. J. Exp. Pathol. 2010. V. 91. № 4. P. 335 – 349.
  15. Chung Y.C., Chang Y.F.Serum interleukin-6 levels reflect the disease status of colorectal cancer // J. Surg. Oncol. 2003. V. 83. P. 222 – 226.
  16. Compérat E., Rouprêt M., Drouin S.J., Camparo P., Bitker M.O., Houlgatte A., Cancel-Tassin G., Cussenot O.Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy //Prostate. 2010. V. 70. № 15. P. 1622 – 1627.
  17. Fagioli F., Biasin E., Mereuta O.M., Muraro M., Luksch R., Ferrari S., Aglietta M., Madon E. Poor prognosis osteosarcoma: new therapeutic approach // Bone Marrow Transplant. 2008. V. 41. Suppl. 2. P. 131 – 134.
  18. Gao L.B., Liang W.B., Xue H., Rao L., Pan X.M., Lv M.L., Bai P., Fang W.L., Liu J., Liao M., Zhang L.Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma // Clin. Chim. Acta. 2009. V. 409.
    № 1-2. P. 132 – 135.
  19. Gao L.B., Rao L., Wang Y.Y., Liang W.B., Li C., Xue H., Zhou B., Sun H., Li Y., Lv M.L., Du X.J., Zhang L.The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer // Carcinogenesis.2009. V. 2. № 2.
    P. 295 – 299.
  20. García-Santos G., Martin V., Rodríguez-Blanco J., Herrera F., Casado-Zapico S., Sánchez-Sánchez A.M., Antolín I., Rodríguez C.Fas/Fas ligand regulation mediates cell death in human Ewing\'s sarcoma cells treated with melatonin //Br. J. Cancer. 2012.
    V. 106. № 7. P. 1288 – 1296.
  21. Gelderblom H., Jinks R.C., Sydes M., Bramwell V.H., van Glabbeke M., Grimer R.J., Hogendoorn P.C., McTiernan A., Lewis I.J., Nooij M.A., Taminiau A.H., Whelan J. European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials // Eur. J. Cancer. 2011.
    V. 47. № 6. P. 895 – 902.
  22. Gimeno R., Lee C.K., Schindler C., Levy D.E.Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes // Mol. Cell Biol. 2005. V. 13. P. 5456 – 5465.
  23. Hamblin A.S. Lymphokines and interleukins // Immunology. 1988. S.1.
    P. 39 – 41.
  24. Harting M.T., Lally K.P., Andrassy R.J., Vaporciyan A.A., Cox C.S.Jr., Hayes-Jordan A., Blakely M.L.Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients //J. Cancer Res. Clin. Oncol. 2010. V. 136. № 4. P. 561 – 570.
  25. Hussain S.P., Harris C.C.Inflammation and cancer: an ancient link with novel potentials // Int. J. Cancer. 2007. V. 121. P. 2373 – 2380.
  26. Inaba H., Glibetic M., Buck S., Ravindranath Y., Kaplan J.Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8 // Pediatr. Blood Cancer. 2004. V. 43. № 7. P. 729 – 736.
  27. Kai H., Kitadai Y., Kodama M., Cho S., Kuroda T., Ito M., Tanaka S., Ohmoto Y., Chayama K. Involvement of proinflammatory cytokines IL-1beta and
    IL-6 in progression of human gastric carcinoma // Anticancer Res. 2005. V.25. P.709– 713.
  28. Kim H.S.Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping // Cytogenet. Cell Genet. 1999. V. 84. P. 93.
  29. Kohyama K., Sugiura H., Kozawa E., Wasa J., Yamada K., Nishioka A., Kamei Y., Taguchi O. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model // Anticancer Res. 2012. V. 32. № 3. P. 779 – 782.
  30. Koike M., Sekigawa I., Okada M., Matsumoto M., Iida N., Hashimoto H., Oshimi K.Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16 // Leuk. Res. 2002. V. 26. P. 705 – 711.
  31. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy // Biomed. Pharmacother. 2001. V. 55. P. 111 – 116.
  32. Kundu J.K., Surh Y.J.Emerging avenues linking inflammation and cancer // Free Radic. Biol. Med. 2012. V. 52. № 9. P. 2013 – 2037.
  33. Laberge S., Cruikshank W.W., Kornfeld H., Center D.M.Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage // J. Immunol. 1995. V. 155. P. 2902 – 2910.
  34. Lejeune F.J., Liénard D., Matter M., Rüegg C. Efficiency of recombinant human TNF in human cancer therapy // Cancer Immun. 2006. V. 6. P. 6.
  35. Li C., Cheng Q., Liu J., Wang B., Chen D., Liu Y.Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma //Mol. Cell Biochem. 2012. V. 364. № 1-2. P. 337 – 344.
  36. Li S., Deng Y., Chen Z.P., Huang S., Liao X.C., Lin L.W., Li H., Peng T., Qin X., Zhao J.M.Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population //Infect. Genet. Evol. 2011. V. 11. № 8. P. 2083 – 2088.
  37. Li Z.,Xu Q.,Peng H., Cheng R., Sun Z., Ye Z.IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway // Int. Immunopharmacol. 2011. V. 11. № 4. P. 496 – 503.
  38. Lin Y.M., Chang Z.L., Liao Y.Y., Chou M.C., Tang C.H.IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma // Cancer Lett. 2013. V. 328. № 1. P. 135 – 143.
  39. Locklin R.M.,Federici E.,Espina B., Russell R.G., Edwards C.M.Selective targeting of death receptor 5 circumvents resistance of MG-63osteosarcoma cells to TRAIL-induced apoptosis //Mol. Cancer Ther. 2007. V. 12. Pt. 1. P. 3219 – 3228.
  40. Lu H., Ouyang W., Huang C.Inflammation, a key event in cancer development // Mol. Cancer Res. 2006. V. 4. P. 221 – 233.
  41. Mackall C.L., Rhee E.H., Read E.J., Khuu H.M., Leitman S.F., Bernstein D., Tesso M., Long L.M., Grindler D., Merino M., Kopp W., Tsokos M., Berzofsky J.A., Helman L.J. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas // Clin. Cancer Res. 2008. V. 14. № 15. P. 4850 – 4858.
  42. Mahindra A., Anderson K.C.Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?// J. Natl. Cancer Inst. 2012. V. 104. № 13. P. 964 – 965.
  43. Markiewicz K., Zeman K., Kozar A., Gołebiowska-Wawrzyniak M. [Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report] // Med. Wieku Rozwoj. 2011. V. 15. № 1. P. 25 – 31.
  44. Mathieu J., Flexor M., Lanotte M., Besançon F.A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNFalpha and all-trans retinoic acid in APL cells // Oncogene.2008. V. 27. № 24. P. 3361 – 3370.
  45. Mathy N.L., Scheuer W., Lanzendörfer M., Honold K., Ambrosius D., Norley S., Kurth R.Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes // Immunology. 2000. V. 100. P. 63 – 69.
  46. Mc Tiernan A., Jinks R.C., Sydes M.R., Uscinska B., Hook J.M., van Glabbeke M., Bramwell V., Lewis I.J., Taminiau A.H., Nooij M.A., Hogendoorn P.C., Gelderblom H., Whelan J.S. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup // Eur. J. Cancer. 2012. V. 48. № 5. P. 703 – 712.
  47. Meda L., Gasperini S., Ceska M., Cassatella M.A.Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by gamma interferon // Cell Immunol. 1994. V. 157. № 2. P. 448 – 461.
  48. Meyer-Wentrup F., Richter G., Burdach S. Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope // Pediatr. Hematol. Oncol. 2005. V. 22. № 4. P. 297 – 308.
  49. Mochizuki Y., Nakanishi H., Kodera Y., Ito S., Yamamura Y., Kato T., Hibi K., Akiyama S., Nakao A., Tatematsu M. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line // Clin. Exp. Metastasis. 2004. V. 21. P. 39 - 47.
  50. Moon M.H., Jeong J.K., Seo J.S., Seol J.W., Lee Y.J., Xue M., Jackson C.J., Park S.Y.Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation //Exp. Mol. Med. 2011. V. 43. № 3. P. 138 – 145.
  51. Morgan D.A., Ruscetti F.W., Gallo R.C. Selective in vitro growth of T lymphocytes from normal human bone marrows // Science. 1976. V. 193. № 4257. P. 1007 – 1008.
  52. Moss S.F., Blaser M.J.Mechanisms of disease: inflammation and the origins of cancer // Nat. Clin. Pract. Oncol. 2005. V. 2. P. 90 – 97.
  53. Muc-Wierzgon M., Nowakowska-Zajdel E., Kokot T., Kozowicz A., Wiczkowski A., Grochowska-Nied­worok E., Mazurek U., Wierzgon J. Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease // J. Biol. Regul. Homeost. Agents.2006. V.20. P.10–14.
  54. Nishimura M., Yuasa K., Mori K., Miyamoto N., Ito M., Tsurudome M., Nishio M., Kawano M., Komada H., Uchida A., Ito Y. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact // J. Orthop. Res. 2005. V. 23. № 5. P. 979 – 987.
  55. Pedersen K.B., Andersen K., Fodstad O., Maelandsmo G.M.Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4 // BMC Cancer. 2004. № 4. P. 52.
  56. Picarda G., Lamoureux F., Geffroy L., Delepine P., Montier T., Laud K., Tirode F., Delattre O., Heymann D., Rédini F.Preclinical evidence that use of TRAIL in Ewing\'s sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival //Clin. Cancer Res. 2010. V. 16. № 8. P. 2363 – 2374.
  57. Rumsaeng V., Cruikshank W.W., Foster B., Prussin C., Kirshenbaum A.S., Davis T.A., Kornfeld H., Center D.M., Metcalfe D.D.Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16 // J. Immunol. 1997. V. 159. P. 2904 – 2910.
  58. Sandoval R., Xue J., Pilkinton M., Salvi D., Kiyokawa H., Colamonici O.R. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines // J. Biol. Chem. 2004. V. 279. № 31. P. 32275 - 32280.
  59. Sato T., Onai N., Yoshihara H., Arai F., Suda T., Ohteki T.Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion // Nat. Med. 2009. V. 15. № 6. P. 696 – 700.
  60. Schneider M.R., Hoeflich A., Fischer J.R.,Wolf E., Sordat B., Lahm H.Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells // Cancer Lett. 2000. V. 151. P. 31 – 38.
  61. Shanmugham L.N., Petrarca C., Frydas S., Donelan J., Castellani M.L., Boucher W., Madhappan B., Tete\' S., Falasca K., Conti P., Vecchiet J. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances // J. Exp. Clin. Cancer Res. 2006. V. 25. P. 529 – 536.
  62. Sharma V., Sparks J.L., Vail J.D.Human B-cell lines constitutively express and secrete interleukin-16 // Immunology. 2000. V. 99. P. 266 – 271.
  63. Sharrow A.C., Li Y., Micsenyi A.Modulation of osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL // Exp. Cell Res. 2008. V. 314. № 2. P. 297 – 308.
  64. Sincovics J.G. Oncogenes and growth factors // Critical Rev. Immunol. 1988. V. 8. № 4. P. 217 – 299.
  65. Smith K.A. T-cell growth factor // Immunol. Rev. 1980. V. 51. P. 337 – 357.
  66. Strander H. Interferons and osteosarcoma // Cytokine Growth Factor Rev. 2007. V. 18. № 5-6. P. 373 – 380.
  67. Tappeiner C., Moller B., Hennig M., Heiligenhaus A. New biologic drugs:anti-interleucin therapy // New Treatments in Noninfectious Uveitis. Dev. Ophtalmol. Basel, Karger. 2012. V. 51. P. 79 – 89.
  68. Taylor R., Knowles H.J., Athanasou N.A.Ewing sarcoma cells express RANKL and support osteoclastogenesis //J. Pathol. 2011. V. 225. № 2. P. 195 – 202.
  69. Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chatterjee N., Welch R., Hutchinson A., Crenshaw A., Cancel-Tassin G., Staats B.J., Wang Z., Gonzalez-Bosquet J., Fang J., Deng X., Berndt S.I., Calle E.E., Feigelson H.S., Thun M.J., Rodriguez C., Albanes D., Virtamo J., Weinstein S., Schumacher F.R., Giovannucci E., Willett W.C., Cussenot O., Valeri A., Andriole G.L., Crawford E.D., Tucker M., Gerhard D.S., Fraumeni J.F.Jr., Hoover R., Hayes R.B., Hunter D.J., Chanock S.J.Multiple loci identified in a genome-wide association study of prostate cancer // Nat. Genet. 2008. V. 40. P. 310 – 315.
  70. Tsagaraki I., Tsilibary E.C., Tzinia A.K.TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcomacell line MG-63 against TNF-α-induced apoptosis//Cell Tissue Res. 2010. V. 342. № 1. P. 87 – 96.
  71. Tu B., Du L., Fan Q.M.,Tang Z., Tang T.T.STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma // Cancer Lett. 2012. V. 325. № 1. P. 80 – 88.
  72. Ullenhag G.J., Spendlove I., Watson N.F., Kallmeyer C., Pritchard-Jones K., Durrant L.G. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55 // Clin. Immunol. 2008. V. 128. № 2. P. 148 – 154.
  73. Waldmann T.A. Multichain interleukin-2 receptor: a
    target for immunotherapy in limphoma // J. Natl. Cancer Ins. 1989. V. 81.
    № 12. P. 914 – 923.
  74. Wenner C.A., Güler M.L., Macatonia S.E., O\'Garra A., Murphy K.M.Roles of IFN-gamma and IFN-alpha in IL-12-induced T hel­per cell-1 development // J. Immunol. 1996.
    V. 156. № 4. P. 1442 – 1447.
  75. Whelan J.S., Jinks R.C., McTiernan A., Sydes M.R., Hook J.M., Trani L., Uscinska B., Bramwell V., Lewis I.J., Nooij M.A., van Glabbeke M., Grimer R.J., Hogendoorn P.C., Taminiau A.H., Gelderblom H. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials // Ann. Oncol. 2012. V. 23. № 6. P. 1607 – 1616.
  76. Wu G., Yu A.X., Zhu S.B., Qi B.W.[Treatment of osteosarcoma with TNF-related apoptosis-inducing ligand or in combination with doxorubicin in animal experiment] //Zhonghua Yi Xue Za Zhi. 2009.
    V. 89. № 37. P. 2644 – 2648.
  77. Yamano Y., Araya N., Sato T., Utsunomiya A., Azakami K., Hasegawa D., Izumi T., Fujita H., Aratani S., Yagishita N., Fujii R., Nishioka K., Jacobson S., Nakajima T.Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder // PLoS One. 2009. V. 4. № 8. E. 6517.
  78. Yellapa A., Bahr J.M., Bitterman P., Abramowicz J.S., Edassery S.L., Penumatsa K., Basu S., Rotmensch J., Barua A.Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer //Int. J. Gynecol. Cancer. 2012. V. 22. № 2. P. 199 – 207.
  79. Young H.A., Hardy K.J.Role of interferon-gamma in immune cell regulation // J. Leukoc. Biol. 1995.
    V. 58. № 4. P. 373 – 381.
  80. Zhu J., Qin C., Yan F., Wang M., Ding Q., Zhang Z., Yin C.IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population //Int. J. Urol. 2010. V. 17. № 8. P. 700 – 707.

© Издательство «РАДИОТЕХНИКА», 2004-2017            Тел.: (495) 625-9241                   Designed by [SWAP]Studio